{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-024945","form_type":"8-K","ticker":null,"cik":"0001504167","company_name":"TREX WIND-DOWN, INC.","filed_at":"2023-08-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.127169+00:00","generated_at":"2026-06-11T01:07:48.445010+00:00","sec_items":["1.01","2.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Timber Pharma secures $3M bridge loan from LEO US Holding; warrant amendments","bullets":["Bridge loan of $3M from LEO US Holding (acquiring parent); $2M funded immediately, $1M on Sep 30, 2023.","Loan secured by all assets; 12% interest; maturity Nov 17, 2023; if third-party acquisition proposal, 1.25x repayment.","Upon merger close, $1.5M principal plus accrued interest extinguished; remaining $1.5M repaid from FDA and net sales milestones.","Warrant holders can elect to convert warrants into merger consideration or receive Black-Scholes cash value; deemed cash if no election."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-024945","json":"https://secwatch.observer/filing/0001437749-23-024945.json","markdown":"https://secwatch.observer/filing/0001437749-23-024945.md","text":"https://secwatch.observer/filing/0001437749-23-024945.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1504167/000143774923024945/0001437749-23-024945-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1504167/000143774923024945/tmbr20230831_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T01:07:48.445010+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d750c3c3d0b22f699e49b39c6ad561a0dfd58ae","claim":"TREX WIND-DOWN, INC. incurred loan of $3.0 million with LEO US Holding, Inc. at 12% per annum maturing November 17, 2023.","evidence_excerpt":"On August 30, 2023, Timber, Timber Pharmaceuticals, LLC, BioPharmX, Inc. and Parent entered into a Secured Bridge Loan Agreement (the \"Bridge Loan Agreement\"), pursuant to which Parent has agreed to loan Timber an aggregate amount of $3.0 million (the \"Bridge Loan\").","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1504167/000143774923024945/0001437749-23-024945-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$3.0 million"},{"label":"Counterparty","value":"LEO US Holding, Inc."},{"label":"Rate","value":"12% per annum"},{"label":"Maturity","value":"November 17, 2023"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"28320fc6f31edfeff552f976d9e2c9c5d10f5e1a","claim":"TREX WIND-DOWN, INC. entered into Secured Bridge Loan Agreement with LEO US Holding, Inc., LEO Pharma A/S valued at $3.0 million (effective 2023-08-30).","evidence_excerpt":"the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ Item 1.01 Entry into a Material Definitive Agreement. As previously announced, on August 20, 2023, Timber Pharmaceuticals, Inc., a Delaware corporation (“Timber” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with LEO US Holding, Inc., a Delaware corporation (“Parent”), LEO Spiny Merger Sub, Inc., a Delaware corporation and direct, wholly-owned subsidiary of Parent (“Merger Sub”) and LEO Pharma A/S, a Danish Aktieselskab (“Guarantor”), providing for, among other things, the merger of Merger Sub with and into Timber (the “Merger”), with Timber surviving the Merger (the “Surviving Corporation”) as a wholly-owned subsidiary of Parent. In connection with the Merger Agreement, on August 30, 2023, Timber, Timber Pharmaceuticals, LLC, BioPharmX, Inc. and","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1504167/000143774923024945/0001437749-23-024945-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"LEO US Holding, Inc., LEO Pharma A/S"},{"label":"Value","value":"$3.0 million"},{"label":"Effective","value":"2023-08-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}